Blood Screening Market Analysis

Technology (Nucleic Acid Testing, Rapid Tests, Western Blot Assay, ELISA, Next-Generation Sequencing)

The ELISA segment in the blood screening market is anticipated to hold the largest gain by the end of 2037. ELISA is a typical laboratory test, done to find antibodies in the blood. They are produced when the immune system of the body recognizes dangerous compounds, known as antigens. The segment growth is primarily attributed to the rising need for testing for COVID-19, and carrying out sexually transmitted diseases testing among the population around the world. As per the World Health Organization, globally, more than 1 million people have STDs. Moreover, as of July 2022, there were nearly 40 million HIV cases all over the world.

End Users (Hospitals, Clinical Laboratories)

Blood screening market from the hospital segment is attributed to holding the largest share of 55 % over the forecast period. As a large patient pool is being admitted to hospitals, owing to which the popularity of hospitals is being increased daily, it is anticipated to bring lucrative growth opportunities for the segment growth. Further, the growing cases of organ transplant surgeries in hospitals are other factors to drive the segment growth.

Our in-depth analysis of the global market includes the following segments:

Technology	Nucleic Acid Testing Rapid Tests Western Blot Assay ELISA Next-Generation Sequencing
Product Type	Reagents & Kits Instruments
End User	Hospitals Clinical Laboratories

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of blood screening is assessed at USD 3.15 billion.

The blood screening market size was over USD 3 billion in 2024 and is poised to reach USD 6.54 billion by the end of 2037, growing at around 6.3% CAGR during the forecast period i.e., between 2025-2037. Rising number of people suffering with chronic diseases, higher blood transfusions and increased cases of infectious diseases will boost the market growth.

North America is set to be the largest with a industry share of about 38% by 2037, driven by higher demand for blood transfusion in the region.

The major players in the market include Abbott Laboratories, Grifols, S.A., Quotient Limited, Thermo Fisher Scientific Inc., BD, Ortho Clinical Diagnostics, DiaSorin S.p.A., Bio-Rad Laboratories, Inc., Danaher Corporation, Beckman Coulter, Inc.

Blood Screening Market Analysis